Abstract library

68 results for "Reig".
#39 Specialist dietetic input and nutritional outcomes in Neuroendocrine Tumour Patients
Introduction: Neuroendocrine tumors (NETs) are a heterogeneous group of tumors that are complex to manage and require a multidisciplinary approach. The most common primary sites are the small intestine and pancreas. The disease itself, as well as sequelae from surgery and medical therapy, can have a negative impact on patients’ nutritional status. Weight loss is known to be a poor prognostic indicator.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: MRS CALEY L SCHNAID
Authors: Schnaid C, Khan M, Davies P, Jamieson A, ...
#82 A case of insulinoma successfully treated by means of long-acting somatostatin analogue
Introduction: Insulinoma is the most common hormonally active pancreatic neuroendocrine tumor. Effective treatment represents tumor surgery and medical therapy using diazoxide or streptozotocine. Somatostatin analogue therapy is rarely effective in this type of tumor.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Prof Marek Bolanowski
#202 Extreme Obesity Due to Insulinoma Within Multiple Endocrine Neoplasia (MEN) 1 Syndrome
Introduction: Peak incidence of symptoms in women with multiple endocrine neoplasia (MEN) 1 is during the third decade of life. Insulinomas are present in 20% of patients and cause weight gain in 30% of patients.
Conference: 8th Annual ENETS Conference (2011)
Category: Clinical
Presenting Author: Ivan Kruljac
Authors: Kruljac I, Vrkljan M, ...
#828 Challenging in Predicting Response in Treatment of Neuroendocrine Pancreatic Tumors: Nutritional Factors
Introduction: Neuroendocrine pancreatic tumors (NEPT) include a heterogeneous neoplasms group in pathophysiology, clinical manifestations, treatment and prognosis.
Conference: 11th Annual ENETS Conference (2014)
Category: Epidemiology/Natural history/Prognosis - Prognosis
Presenting Author: MD Cristina Tejera
#923 A Case Report of a Pancreatic Neuroendocrine Tumor (pNET) With High Levels of 5-HIAA in Urine
Introduction: A 79-year-old man presented with weakness and weight loss. Clinical examination revealed a palpable liver and CT scan a mass in the head of pancreas and multiple liver lesions.
Conference: 11th Annual ENETS Conference (2014)
Category: Clinical cases/reports
Presenting Author: Dr Nikolaos Tsoukalas
Keywords: 5-HIAA, pancreas, pNET
#1292 The Role of 68Ga- DOTA-NOC PET in Evaluating Neuroendocrine Tumors: Real-World Experience from Single Lebanese Institution.
Introduction: Functional imaging with somatostatin analogues have been commonly used in NETs
Conference: 13th Annual ENETS conference (2016)
Category: Imaging (radiology, nuclear medicine, endoscopy)
Presenting Author: Dr Rita Assi
Keywords: NET, Gallium PET
#1331 The Symptoms Experienced by Small Bowel and Pancreatic NET Patients Prior to Diagnosis Do Not Meet the Criteria for a Functional Diarrhoea (IBS-D) Diagnosis
Introduction: Patients with neuroendocrine tumours (NETs) complain of symptoms that may be mistaken for irritable bowel syndrome (IBS). There is no clear data if these symptoms overlap with those of IBS or if differentiating symptoms co-exist.
Conference: 13th Annual ENETS conference (2016)
Category: Epidemiology/Natural history/Prognosis - Registries, nationwide and regional surveys
Presenting Author: Dr Ron Basuroy
#2098 Systemic Anti-Cancer Therapies in Neuroendocrine Tumor Patients Impair Nutritional Status
Introduction: Malnutrition is a clinical relevant problem in NEN-patients (pts) independently influencing overall prognosis, particularly in pts undergoing chemotherapy (CTx). A poor nutritional status (NS) in pts of all WHO-grades was associated with a significantly shorter long-term outcome
Conference: 15th Annual ENETS conference (2018)
Category: Medical treatment - others, not specified
Presenting Author: Sophie Pevny
#2147 Nutritional Assessment and Vitamin Deficiencies in Patients with NETs
Introduction: As a result of disease or related to its management, patients with neuroendocrine tumours may have altered gut or pancreatic function that can cause nutritional deficiencies.
Conference: 15th Annual ENETS conference (2018)
Category: Epidemiology/Natural history/Prognosis- Registries, nationwide and regional surveys
Presenting Author: Mark Reynolds
Authors: Lim S, Reynolds M, Rees D A, Chaudhry R, ...
#79 PTOV-1 overexpression in neuroendocrine tumors: a new molecular marker
Introduction: PTOV-1 (Prostate Tumor Overexpressed-1) is a novel protein encoded by 12-exon gene localized in chromosome 19q.13.3. Recently identified as an androgen-induced gene, it is involved in prostate cell proliferation and in prostate human cancer. PTOV-1 expression has been demonstrated in neuroendocrine cells of normal prostate tissue. Preliminary data indicate that PTOV-1 can be related to flotilin, integrins and other cellular factors involved in cancer progression.
Conference: 7th Annual ENETS Conference (2010)
Category: Basic
Presenting Author: MD INES DE TORRES